AVCT
NEUTRALAvacta Provides Q2 2025 Business Update
The biotechnology company provides a business update on the progress of its pipeline and changes to its management team and board.
Avacta Group
30.50GBX
0.00%
Market Cap
119.97M
Volume
43k
2% of avg
P/E Ratio
-0.03
EPS (TTM)
-9.46
Beta
-0.28
Day Range
0.00p - 0.00p
52 Week Range
0.00p30.50p86.40p
30.50p
Upcoming Events
AVCT
NEUTRALAvacta Appoints New Chief Medical Officer and Business Development Advisor
The biotechnology company has appointed a new Chief Medical Officer and a business development advisor to strengthen its leadership team.
AVCT
NEUTRALAvacta Appoints Zeus Capital as Joint Broker
The healthcare company has appointed Zeus Capital as a joint broker, joining existing brokers Peel Hunt and Panmure Liberum.
AVCT
NEUTRALAvacta Reports New Response in FAP-Dox Phase 1b Trial
The life sciences company reports a new partial response in the dose expansion phase of its FAP-Dox Phase 1b trial for salivary gland cancer, a rare tumor type with high unmet need.
AVCT
NEUTRALAvacta Group Announces Posting of Annual Report and Revised Notice of AGM
The life sciences company provides details on the availability of its annual report and revised notice for the upcoming annual general meeting.
AVCT
BADAvacta Group Reports Widening Losses as It Transitions to Pure-Play Oncology Company
The biopharmaceutical company reported widening losses and a significant revenue decline as it transitions to a pure-play oncology focus. Despite clinical progress, financial pressures and development risks loom large.
AVCT
NEUTRALAvacta Delays Preliminary Results Announcement
The healthcare company has pushed back the release of its preliminary results for the year ended December 31, 2024.
AVCT
NEUTRALAvacta Appoints New Non-Executive Directors
The healthcare company has appointed two experienced industry executives to its board of directors.
AVCT
NEUTRALAvacta Delays Preliminary Results Announcement
The healthcare company has pushed back the release of its preliminary results for the year ended December 31, 2024 due to audit work delays.
AVCT
NEUTRALAvacta Group Announces Upcoming Results Presentation
The biotechnology company will announce its audited preliminary results for the year ended December 31, 2024 and host an investor presentation on May 29, 2025.